Please login to the form below

Not currently logged in
Email:
Password:

BioCryst Appoints new senior vice-president of regulatory affairs

US-based BioCryst Pharmaceuticals hires Dr Elliott T Berger as senior vice-president of regulatory affairs

US-based BioCryst Pharmaceuticals has hired Dr Elliott T Berger as senior vice-president of regulatory affairs.

Dr Berger brings to BioCryst a long and successful track record in obtaining approval from the FDA for numerous drugs. He will play an integral role in BioCryst's planned clinical research programmes for treatments for influenza, leukaemia and lymphoma, autoimmune diseases and transplant rejection, and will work in close collaboration with health authorities in the US and other countries.

Berger has more than 30 years of experience in the pharmaceutical industry, including over 25 years devoted to management of regulatory affairs supporting new drug and biologic development. Most recently he was vice-president of regulatory affairs and quality assurance and head of global regulatory strategy at EMD Pharmaceuticals, the North American subsidiary of Germany-headquartered Merck KGaA.

Berger held a variety of research positions at Merck Research Laboratories in West Point, Pennsylvania, most recently as Senior Director, Regulatory Liaison. He has submitted and managed over 10 New Drug Applications and numerous Investigational Drug Applications in the areas of oncology, diabetes, cardiovascular disease, and neurology.

8th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics